BIOPHTA, a France-based preclinical biotech company developing technology solutions for the treatment of eye diseases, has raised €6.5 million (approximately $7 million) in seed funding in the just concluded financing round to propel its patented technology to a clinical development stage. As the company announced today, the funding round, led by UI Investissement through the BIOPHTA will use the seed capital to advance its patented eye disease treatment technology to the clinical development stage targeting leading causes of blindness such as Glaucoma and Macular Edema.
read more..